Stifel Nicolaus reiterated its Buy rating on Endo Health Solutions ENDP but reduced its price target from $44 to $40.
Stifel Nicolaus noted, "Facing generic entry from Impax on its older, non tamper-resistant formulation (non-TRF) of Opana ER on 1/1/13, Endo had hoped to force a decision from FDA (through a lawsuit) before year-end regarding 1) its withdrawal of non-TRF for safety reasons, 2) imminent entry of generics and 3) withdrawals of ANDAs referencing the old formulation. FDA does not intend to have a decision in that time-frame, opening the door for further competition on Opana ($300mn+). After a difficult 2012, we see near-term Opana headwinds given what we believe is near-certain generic entry."
Endo Health Solutions closed at $28.29 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in